ClinicalTrials.gg
CompletedNCT00606632Updated Oct 2, 2018Results posted

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

A Phase 3 interventional study of 124-Iodine-cG250 (124I-cG250) and CT in Renal Cell Carcinoma and Kidney Cancer, sponsored by Heidelberg Pharma AG. Completed at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-02.

Sponsored by Heidelberg Pharma AG · Phase 3, Interventional, and Diagnostic

Phase
Phase 3
Study type
Interventional
Enrollment
226
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 1,142 studies in Carcinoma, Renal Cell with a site in United States — 157 open to participants now, 280 under way, 26 of them phase 3. Carcinoma, Renal Cell · United States.

Enrollment
128th of 1,008
226 · median 40
Started
2008
with 42 others
Phase 3
73 of 1,142
8 open now
Registered
298th of 1,142
by date

Among the 1,142 studies in Carcinoma, Renal Cell with a site in United States, this one is the 128th largest by enrollment of the 1,008 interventional ones, is one of 43 that started in 2008, is one of 73 in phase 3, and was the 298th registered.

By phase

1,142 studies; the count open now beside each. This study's row is marked.

Phase 2382 · 46 open
Phase 1342 · 38 open
Phase 1/2146 · 31 open
No phase98 · 15 open
Observational87 · 17 open
Phase 3this study73 · 8 open
Phase 410 · 2 open
Other kind3 · 0 open
Phase 2/31 · 0 open

By the year they started

First in 1990; this study’s year is marked. 43 started in 2008.

Size and results

Median enrollment 40 across the 1,008 interventional studies, 100 across the 87 observational. Of the 791 that completed or were terminated, 335 (42%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 1,142 studies in Carcinoma, Renal Cell with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter Phase III study to demonstrate the diagnostic utility of 124I-cG250 PET/CT pre-surgical imaging in patients with operable renal masses.

Read the detailed description

A preoperative 124I-cG250 PET scan may distinguish between clear cell and non-clear cell renal carcinoma in patients with renal masses. Studies of imaging characteristics of 124I by a variety of PET cameras, quantification of tumor uptake of 124I-labeled antibody and correlation with biopsy measurement of tumor and normal tissue have met with encouraging results. As clear cell renal cancers are associated with an aggressive phenotype their a priori determination may help guide appropriate surgical/therapeutic management.

03

Conditions studied

  • Renal Cell Carcinoma
  • Kidney Cancer

Keywords

  • Renal Mass
  • Clear Cell Renal Cell Carcinoma
  • Cancer of Kidney
  • Kidney Cancer
  • Neoplasms
  • cG250
  • antibody, monoclonal
  • Iodine 124
  • Positron-Emission Tomography
  • Kidney
  • Renal Cancer
  • Renal Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is over 18 years of age.
  • Presence of a renal mass.
  • Scheduled for surgical resection of renal mass (partial or total nephrectomy, open or laparoscopic technique).
  • Expected survival of at least 3 months.
  • (ECOG) performance status \< 2.
  • The following laboratory results should be within the following limits within the last 2 weeks prior to study day 1:

    • (ANC) ≥ 1.5 x 109/L
    • count ≥ 100 x 109/L
    • Serum ≤ 2.0 mg/dL
    • (AST) ≤ 2.5 x
    • Alanine aminotransferase (ALT) ≤ 2.5 x ULN
    • Serum creatinine ≤ 2.0 mg/dL (calculated >45 ml/min)
  • Negative serum pregnancy test; to be performed on female patients of within 24 hours prior to receiving product. All females of childbearing potential must indicate intent to avoid pregnancy and must use an accepted, effective method of for the duration of the study.
  • Recovered from toxicity of any prior therapy.
  • Able and willing to give valid written .

Exclusion criteria

Exclusion Criteria:

  • of primary tumor other than Renal Cell Carcinoma (RCC).
  • Prior history of within the last 5 years.
  • Prior exposure to murine proteins or chimeric antibodies.
  • Intercurrent medical condition that may limit the amount of antibody to be administered.
  • Intercurrent medical condition that renders the patient ineligible for surgery.
  • Class III/IV cardiac disease.
  • History of hepatitis.
  • Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to 124I-cG250 infusion on day 1.
  • Mental impairment that may compromise the ability to give and comply with the requirements of the study.
  • Lack of availability for immunological and clinical follow-up assessments.
  • Participation in any other clinical trial involving another product within 4 weeks prior to enrolment.
  • Women who are pregnant or breastfeeding.
  • Allergy to iodine, hyperthyroidism, or Grave's Disease.
  • Known allergic reaction to human serum albumin.
  • for contrast-enhanced CT or PET/CT.
  • Contraindication to potassium iodide intake (see package insert).
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
226 participants (actual)

Study arms

  • Other
    124-Iodine-cG250 (124I-cG250)

    Single arm study, comparing 124I cG250 PET/CT and CT. Each patient underwent a PET/CT and CT scan days (+/-2days) after receipt of 124I cG250.

    Drug: 124-Iodine-cG250 (124I-cG250) · Procedure: CT

Interventions

06

What researchers measure

Primary outcomes

  1. Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT.

    Average estimate of three independent, blinded central readers per imaging modality on the proportion of participants that were correctly identified on the 124I-cG250 PET/CT Images of having (sensitivity) or not having (specificity) clear cell renal carcinoma (ccRCC) compared to CT images. Histopathology provided the standard-of-truth because it is the only definitive method for accurately identifying ccRCC.

    Time frame: 6 months

Secondary outcomes

  1. Accuracy of 124I-cG250 PET/CT Imaging Versus Diagnostic CT Imaging

    The Accuracy is the proportion of participants with correct determinations of 124I-cG250 PET/CT imaging compared to diagnostic CT Imaging in the detection of ccRCC as confirmed by histopathology diagnoses. The numbers represent the average estimate of three independent, blinded central readers per imaging modality. For the secondary efficacy variables no 95% CIs for differences of averages were calculated.

    Time frame: 6 months

  2. Positive Predictive Value (PPV)

    The Positive Predictive Value (PPV) reflects the Proportion of positive results that are true positive. The PPV of 124I-cG250 PET/CT imaging compared to diagnostic CT Imaging in the detection of ccRCC as confirmed by histopathology diagnoses. The numbers represent the average estimate of three independent, blinded central readers per imaging modality. For the secondary efficacy variables no 95% CIs for differences of averages were calculated.

    Time frame: 6 months

  3. Negative Predictive Value (NPV)

    Negative Predictive Value (NPV) reflects the proportion of negative results that are true negatives. The NPV of 124I-cG250 PET/CT imaging compared to diagnostic CT Imaging in the detection of ccRCC as confirmed by histopathology diagnoses. The numbers represent the average estimate of three independent, blinded central readers per imaging modality. For the secondary efficacy variables no 95% CIs for differences of averages were calculated.

    Time frame: 6 months

07

Results

Posted Apr 14, 2014

Participant flow

226 subjects were enrolled at 14 study sites in the USA.

Participant flow — Overall Study
MilestonePET/CT Versus CT
Started226
Completed204
Not completed22
Withdrew: Withdrawal by subject13
Withdrew: Miscellaneous reasons9

Outcome measures

PrimarySensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT.

Average estimate of three independent, blinded central readers per imaging modality on the proportion of participants that were correctly identified on the 124I-cG250 PET/CT Images of having (sensitivity) or not having (specificity) clear cell renal carcinoma (ccRCC) compared to CT images. Histopathology provided the standard-of-truth because it is the only definitive method for accurately identifying ccRCC.

Time frame:
6 months
Reported as:
Mean · Proportion of participants
Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT.
Proportion of participantsSensitivity CTSensitivity PET/CTSpecificity PET/CTSpecificity CT
Sensitivity and Specificity of 124I-cG250 PET/CT Versus Diagnostic CT.0.76 (0.63 to 0.88)0.86 (0.75 to 0.97)0.86 (0.69 to 1.0)0.47 (0.19 to 0.75)
Statistical analysis
  • Sensitivity CT vs Sensitivity PET/CT · McNemar · p = 0.023
  • Specificity PET/CT vs Specificity CT · McNemar · p = <0.01
SecondaryAccuracy of 124I-cG250 PET/CT Imaging Versus Diagnostic CT Imaging

The Accuracy is the proportion of participants with correct determinations of 124I-cG250 PET/CT imaging compared to diagnostic CT Imaging in the detection of ccRCC as confirmed by histopathology diagnoses. The numbers represent the average estimate of three independent, blinded central readers per imaging modality. For the secondary efficacy variables no 95% CIs for differences of averages were calculated.

Time frame:
6 months
Reported as:
Number · Proportion of participants
Accuracy of 124I-cG250 PET/CT Imaging Versus Diagnostic CT Imaging
Proportion of participantsPET/CTDiagnostic CT
Accuracy of 124I-cG250 PET/CT Imaging Versus Diagnostic CT Imaging0.860.68
SecondaryPositive Predictive Value (PPV)

The Positive Predictive Value (PPV) reflects the Proportion of positive results that are true positive. The PPV of 124I-cG250 PET/CT imaging compared to diagnostic CT Imaging in the detection of ccRCC as confirmed by histopathology diagnoses. The numbers represent the average estimate of three independent, blinded central readers per imaging modality. For the secondary efficacy variables no 95% CIs for differences of averages were calculated.

Time frame:
6 months
Reported as:
Number · Protportion of participants
Positive Predictive Value (PPV)
Protportion of participantsPET/CTDiagnostic CT
Positive Predictive Value (PPV)0.940.80
SecondaryNegative Predictive Value (NPV)

Negative Predictive Value (NPV) reflects the proportion of negative results that are true negatives. The NPV of 124I-cG250 PET/CT imaging compared to diagnostic CT Imaging in the detection of ccRCC as confirmed by histopathology diagnoses. The numbers represent the average estimate of three independent, blinded central readers per imaging modality. For the secondary efficacy variables no 95% CIs for differences of averages were calculated.

Time frame:
6 months
Reported as:
Number · Proportion of participants
Negative Predictive Value (NPV)
Proportion of participantsPET/CTDiagnostic CT
Negative Predictive Value (NPV)0.690.41

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PET/CT Versus CT—33/226 (14.6%)191/226 (84.5%)
Most frequent serious events
Showing 10 of 33
Most frequent serious events
EventPET/CT Versus CT
Urinary anastomotic leakInjury, poisoning and procedural complications3/226
Pleural effusionRespiratory, thoracic and mediastinal disorders3/226
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/226
HaematomaVascular disorders3/226
Abdominal painGastrointestinal disorders2/226
DyspnoeaRespiratory, thoracic and mediastinal disorders2/226
HaematuriaRenal and urinary disorders2/226
NauseaGastrointestinal disorders1/226
ConstipationGastrointestinal disorders1/226
VomitingGastrointestinal disorders1/226
Most frequent other events
Showing 10 of 15
Most frequent other events
EventPET/CT Versus CT
NauseaGastrointestinal disorders44/226
Procedural painInjury, poisoning and procedural complications27/226
ConstipationGastrointestinal disorders26/226
FatigueGeneral disorders26/226
Abdominal painGastrointestinal disorders25/226
HeadacheNervous system disorders24/226
DiarrhoeaGastrointestinal disorders19/226
Incision site painInjury, poisoning and procedural complications19/226
InsomniaPsychiatric disorders19/226
Back painMusculoskeletal and connective tissue disorders15/226

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PET/CT Versus CT
<=18 years0
Between 18 and 65 years167
>=65 years59
Age, Continuous
Age, Continuous(years)PET/CT Versus CT
Mean56.1 ± 12.01
Sex: Female, Male
Sex: Female, Male(Participants)PET/CT Versus CT
Female84
Male142
Region of Enrollment
Region of Enrollment(participants)PET/CT Versus CT
United States226
08

Study locations

14 sites
  • David Geffen School of Medicine, UCLA
    Los Angeles, California 90095-1721, United States
  • Stanford University Medical Center
    Stanford, California 94305, United States
  • H. Lee Moffitt Cancer Center & Research Center
    Tampa, Florida 33612, United States
  • Lahey Clinic
    Burlington, Massachusetts 01805, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-0330, United States
  • Nevada Cancer Institute
    Las Vegas, Nevada 89135, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10021, United States
  • UNC School of Medicine-Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University Medical Center
    Durham, North Carolina 27711, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19104-4283, United States
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104-4283, United States
  • MD Anderson
    Houston, Texas 77030-4009, United States
09

References and documents

Publications

  • Divgi CR, Pandit-Taskar N, Jungbluth AA, Reuter VE, Gonen M, Ruan S, Pierre C, Nagel A, Pryma DA, Humm J, Larson SM, Old LJ, Russo P. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol. 2007 Apr;8(4):304-10. doi: 10.1016/S1470-2045(07)70044-X. PubMed 17395103 ↗
  • Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo JA, Larson S, Bevan P, Russo P. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J Clin Oncol. 2013 Jan 10;31(2):187-94. doi: 10.1200/JCO.2011.41.2445. Epub 2012 Dec 3. Erratum In: J Clin Oncol. 2018 Jan 1;36(1):98. doi: 10.1200/JCO.2017.76.9950. PubMed 23213092 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Nov 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2008
First posted
Feb 4, 2008
Start
Mar 2008
Primary completionActual
Nov 2009
CompletionActual
Dec 2009
Results first posted
Apr 14, 2014
Last update
Oct 2, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00606632
Lead sponsor
Heidelberg Pharma AG
Responsible party
Sponsor
First posted
Feb 4, 2008
Start date
Mar 2008
Primary completion
Nov 2009
Completion
Dec 2009
Results posted
Apr 14, 2014
Last update
Oct 2, 2018

Study contacts

Chaitanya Divgi, MD
principal investigator · University of Pennsylvania

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Girentuximab I-124

Start the discussion